- Datum25.09.2023
- Uhrzeit18:30 - 19:30 Uhr
- Veranstalter
LYNX
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Erhalte jetzt Zugriff auf konkrete Trading- und Investmentideen Deiner stock3-Experten mit stock3 Trademate.
GENMAB AS Kurse
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
VK | ||||||
VK | ||||||
VK |
Passende Produkte
Wertentwicklung (L&S)
Wikifolio
Passender Service zu GENMAB AS
Webinar zu GENMAB AS
Kursinformationen (L&S)
- Tagestief / Hoch-
- 52W-Tief / Hoch319,400-449,500
- Jahrestief / Hoch322,400-410,500
Wichtigste Eigenschaften
Dividenden von GENMAB AS
Termine von GENMAB AS
Beschreibung
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.
Pivot-Points (L&S)
- Pivot-HBOP - R3359,867 €
- Pivot-Resist - R2355,933 €
- Pivot-High - R1348,267 €
- Pivotpunkt344,333 €
- Pivot-Low - S1336,667 €
- Pivot-Support - S2332,733 €
- Pivot-LBOP - S3325,067 €